Financial reports
10-Q
2024 Q3
Quarterly report
12 Nov 24
10-Q
2024 Q2
Quarterly report
14 Aug 24
10-Q
2024 Q1
Quarterly report
9 May 24
10-K
2023 FY
Annual report
14 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
5 May 23
10-K
2022 FY
Annual report
23 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
Current reports
8-K
Tectonic Announces $185 Million Private Placement
3 Feb 25
8-K
Regulation FD Disclosure
30 Jan 25
8-K
Regulation FD Disclosure
13 Jan 25
8-K
Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights
7 Nov 24
8-K
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45
19 Sep 24
8-K
Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights
14 Aug 24
8-K
Tectonic Therapeutic Announces US IND Clearance for Lead Program, TX45
30 Jul 24
8-K
Departure of Directors or Certain Officers
5 Jul 24
8-K
Transforming and Innovating the Discovery and Development of Novel, Class Leading GPCR-Targeted TherapiesJ u n e 2 0 2 4
25 Jun 24
8-K
Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million
20 Jun 24
Registration and prospectus
D
$185.03 mm in equity, sold $185.03 mm, 29 investors
14 Feb 25
424B5
Prospectus supplement for primary offering
12 Feb 25
424B5
Prospectus supplement for primary offering
12 Feb 25
424B3
Prospectus supplement
12 Feb 25
S-8 POS
Registration of securities for employees (post-effective amendment)
27 Aug 24
S-8
Registration of securities for employees
21 Aug 24
424B3
Prospectus supplement
14 Aug 24
424B5
Prospectus supplement for primary offering
30 Jul 24
424B3
Prospectus supplement
30 Jul 24
S-1
IPO registration
19 Jul 24
Proxies
DEF 14A
Definitive proxy
1 May 23
DEFA14A
Additional proxy soliciting materials
27 Apr 22
DEF 14A
Definitive proxy
27 Apr 22
DEFA14A
Additional proxy soliciting materials
22 Apr 21
DEF 14A
Definitive proxy
22 Apr 21
DEFA14A
Additional proxy soliciting materials
22 Apr 20
DEF 14A
Definitive proxy
22 Apr 20
DEFA14A
Additional proxy soliciting materials
26 Apr 19
DEF 14A
Definitive proxy
26 Apr 19
Other
EFFECT
Notice of effectiveness
31 Jul 24
EFFECT
Notice of effectiveness
6 May 24
EFFECT
Notice of effectiveness
15 Jan 20
CORRESP
Correspondence with SEC
10 Jan 20
CORRESP
Correspondence with SEC
2 Jan 20
UPLOAD
Letter from SEC
27 Dec 19
EFFECT
Notice of effectiveness
11 Jul 19
CORRESP
Correspondence with SEC
8 Jul 19
UPLOAD
Letter from SEC
3 Jul 19
CT ORDER
Confidential treatment order
21 Jun 18
Ownership
SC 13G/A
BML Investment Partners, L.P.
13 Feb 25
SC 13G
Deep Track Capital, LP
10 Feb 25
SC 13D/A
SPRINGER TIMOTHY A
10 Feb 25
SC 13D/A
Vida Ventures II, LLC
7 Feb 25
SC 13D/A
MCGUIRE TERRANCE
7 Feb 25
4
TIMOTHY A SPRINGER
7 Feb 25
4
Daniel Lochner
7 Feb 25
4
Peter McNamara
6 Feb 25
4
Marc Schwabish
6 Feb 25
4
Daniel Lochner
6 Feb 25